Glucagon-like peptide-1 (GLP-1) analogs have emerged as a compelling therapeutic avenue for managing metabolic conditions. These naturally occurring molecules are secreted by the gut in response to nutrient intake, stimulating insulin production and suppressing glucagon release. GLP-1 peptides demonstrate promising therapeutic results in treating t